Integra Lifesciences (NASDAQ:IART) received a $62.00 price target from equities research analysts at Wells Fargo & Co in a report issued on Friday, TipRanks reports. The brokerage currently has a “hold” rating on the life sciences company’s stock. Wells Fargo & Co‘s target price suggests a potential upside of 8.51% from the stock’s previous close.
IART has been the topic of several other research reports. ValuEngine raised Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Friday. Zacks Investment Research raised Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a research note on Monday, September 2nd. TheStreet lowered Integra Lifesciences from an “a-” rating to a “c+” rating in a research note on Thursday. Oppenheimer upped their target price on Integra Lifesciences from $65.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Finally, JMP Securities upped their target price on Integra Lifesciences to $75.00 in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. Integra Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $61.67.
Shares of NASDAQ:IART traded up $1.41 during trading on Friday, hitting $57.14. 34,701 shares of the stock were exchanged, compared to its average volume of 330,544. The company has a fifty day moving average price of $60.53 and a two-hundred day moving average price of $56.16. The company has a market cap of $4.79 billion, a PE ratio of 23.63, a P/E/G ratio of 1.73 and a beta of 1.10. The company has a current ratio of 2.76, a quick ratio of 1.82 and a debt-to-equity ratio of 0.99. Integra Lifesciences has a 12-month low of $42.14 and a 12-month high of $65.09.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Thursday, October 24th. The life sciences company reported $0.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.03. The business had revenue of $379.10 million for the quarter, compared to analyst estimates of $376.85 million. Integra Lifesciences had a return on equity of 16.79% and a net margin of 3.99%. The company’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.59 EPS. Equities research analysts anticipate that Integra Lifesciences will post 2.74 earnings per share for the current fiscal year.
In other Integra Lifesciences news, VP John Mooradian sold 9,249 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.53, for a total transaction of $578,339.97. Following the transaction, the vice president now owns 18,706 shares of the company’s stock, valued at approximately $1,169,686.18. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Richard E. Caruso sold 520,000 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $60.97, for a total value of $31,704,400.00. Following the transaction, the insider now directly owns 134,134 shares in the company, valued at approximately $8,178,149.98. The disclosure for this sale can be found here. In the last ninety days, insiders sold 877,041 shares of company stock worth $53,469,885. 4.50% of the stock is owned by corporate insiders.
Institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC purchased a new position in shares of Integra Lifesciences during the 2nd quarter worth $26,000. Quadrant Capital Group LLC lifted its stake in shares of Integra Lifesciences by 239.0% during the 3rd quarter. Quadrant Capital Group LLC now owns 556 shares of the life sciences company’s stock worth $31,000 after purchasing an additional 392 shares during the period. World Asset Management Inc purchased a new position in shares of Integra Lifesciences during the 3rd quarter worth $200,000. Zions Bancorporation N.A. lifted its stake in shares of Integra Lifesciences by 5.9% during the 2nd quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock worth $243,000 after purchasing an additional 242 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Integra Lifesciences by 8.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,581 shares of the life sciences company’s stock worth $275,000 after purchasing an additional 360 shares during the period. 81.91% of the stock is currently owned by institutional investors.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Story: Trading Options- What is a Strangle?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.